Literature DB >> 25832177

Atypical femur fracture during bisphosphonate drug holiday: a case series.

A J Lovy1, S M Koehler2, A Keswani2, D Joseph2,3, R Hasija3, R Ghillani2,3.   

Abstract

Recent studies have noted an increased risk of low energy subtrochanteric and femoral shaft fractures termed "atypical femur fractures" (AFFs) associated with long-term bisphosphonate use. As such, many clinicians have begun recommending a "drug holiday" to reduce the risks associated with long-term bisphosphonate use. We present two cases of AFFs occurring during a 4-year or greater drug holiday following long-term bisphosphonate use. These findings highlight the need to reevaluate optimal bisphosphonate therapy duration, dosage, as well as initiation and duration of a drug holiday with continued monitoring in the prevention of AFFs.

Entities:  

Keywords:  Atypical femur fractures; Bisphosphonates; Drug holiday; Osteoporosis

Mesh:

Substances:

Year:  2015        PMID: 25832177     DOI: 10.1007/s00198-015-3063-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  32 in total

Review 1.  Bisphosphonate-associated fractures of the femur: pathophysiology and treatment.

Authors:  Thomas A Einhorn; Yelena Bogdan; Paul Tornetta
Journal:  J Orthop Trauma       Date:  2014-07       Impact factor: 2.512

Review 2.  Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review.

Authors:  Erik F Eriksen; Adolfo Díez-Pérez; Steven Boonen
Journal:  Bone       Date:  2013-10-09       Impact factor: 4.398

3.  Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy.

Authors:  B J X Teo; J S B Koh; S K Goh; M A Png; D T C Chua; T S Howe
Journal:  Bone Joint J       Date:  2014-05       Impact factor: 5.082

4.  Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features.

Authors:  Andrea Giusti; Neveen A T Hamdy; Olaf M Dekkers; Sharita R Ramautar; Sander Dijkstra; Socrates E Papapoulos
Journal:  Bone       Date:  2010-12-31       Impact factor: 4.398

5.  Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis.

Authors:  Orlaith Brennan; Oran D Kennedy; T Clive Lee; Susan M Rackard; Fergal J O'Brien
Journal:  J Orthop Res       Date:  2010-09-30       Impact factor: 3.494

6.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

7.  Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008.

Authors:  Ethel S Siris; Margaret K Pasquale; Yiting Wang; Nelson B Watts
Journal:  J Bone Miner Res       Date:  2011-01       Impact factor: 6.741

Review 8.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

9.  Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.

Authors:  Matthew R Allen; David B Burr
Journal:  J Bone Miner Res       Date:  2007-11       Impact factor: 6.741

Review 10.  Bisphosphonate mechanism of action.

Authors:  Alfred A Reszka; Gideon A Rodan
Journal:  Curr Rheumatol Rep       Date:  2003-02       Impact factor: 4.686

View more
  4 in total

1.  Atraumatic segmental atypical femur fracture secondary to bisphosphonate use: A case report.

Authors:  Andrew J Lovy; Diana Patterson; Laura Skeeles; Richard Ghillani; David Joseph; Yangguan Wu; Rohit Hasija
Journal:  J Clin Orthop Trauma       Date:  2017-03-19

2.  The utility of bone scintigraphy in the assessment of mandibular metabolism during long-term bisphosphonate administration.

Authors:  Yumiko Ohbayashi; Fumi Nakai; Akinori Iwasaki; Takaaki Ogawa; Yuka Yamamoto; Yoshihiro Nishiyama; Minoru Miyake
Journal:  Odontology       Date:  2016-10-21       Impact factor: 2.634

Review 3.  A proposal for an atypical femur fracture treatment and prevention clinical practice guideline.

Authors:  R Dell; D Greene
Journal:  Osteoporos Int       Date:  2018-04-19       Impact factor: 4.507

4.  Bilateral atypical fractures of the femur: Ten years AFTER ten years of bisphosphonate therapy.

Authors:  Matthew D Smith; Olen J Haseman; Jorge A Velez Garza; Jan M Bruder
Journal:  Bone Rep       Date:  2021-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.